Literature DB >> 3960693

The quinolones in chronic bronchitis.

B I Davies, F P Maesen, J P Teengs, C Baur.   

Abstract

Results are presented from 186 hospitalized patients treated for acute purulent exacerbations of chronic bronchitis with orally administered ciprofloxacin (80 patients), enoxacin (26 patients), ofloxacin (30 patients) or pefloxacin (50 patients). In general, good clinical results were observed in 50-70% of the patients treated, most failures being due to relapses or reinfections with Streptococcus pneumoniae or Pseudomonas aeruginosa. Studies on blood and sputum concentration suggested that gastro-intestinal absorption was not always satisfactory. Unwanted drug effects were noted with all agents studied, generally presenting as stomach pain, nausea, hallucinations, or dizziness. Most adverse drug reactions were seen with enoxacin, often but not always during concomitant treatment with theophylline.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3960693     DOI: 10.1007/bf01975481

Source DB:  PubMed          Journal:  Pharm Weekbl Sci        ISSN: 0167-6555


  11 in total

1.  Studies on the treatment with antibacterial drugs of acute and chronic mucopurulent bronchitis caused by Hemophilus influenzae.

Authors:  J MULDER; W R O GOSLINGS; M C VAN DER PLAS; P L CARDOZO
Journal:  Acta Med Scand       Date:  1952-05-10

2.  Quinolones and raised plasma concentrations of theophylline.

Authors:  F P Maesen; J P Teengs; C Baur; B I Davies
Journal:  Lancet       Date:  1984-09-01       Impact factor: 79.321

3.  Enoxacin raises plasma theophylline concentrations.

Authors:  W J Wijnands; C L van Herwaarden; T B Vree
Journal:  Lancet       Date:  1984-07-14       Impact factor: 79.321

4.  Cross-resistance among cinoxacin, ciprofloxacin, DJ-6783, enoxacin, nalidixic acid, norfloxacin, and oxolinic acid after in vitro selection of resistant populations.

Authors:  A L Barry; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  1984-06       Impact factor: 5.191

5.  Cefoperazone in acute exacerbations of chronic bronchitis.

Authors:  B I Davies; F P Maesen; J Brouwers
Journal:  J Antimicrob Chemother       Date:  1982-02       Impact factor: 5.790

6.  Serum and sputum concentrations of enoxacin after single oral dosing in a clinical and bacteriological study.

Authors:  B I Davies; F P Maesen; J P Teengs
Journal:  J Antimicrob Chemother       Date:  1984-09       Impact factor: 5.790

7.  Twice daily dosage of bacampicillin in chronic bronchitis. A double-blind study.

Authors:  B I Davies; F P Maesen; P J Brombacher; J Sjövall
Journal:  Scand J Respir Dis       Date:  1978-10

8.  Serum and sputum antibiotic levels after ampicillin, amoxycillin and bacampicillin chronic bronchitis patients.

Authors:  B Davies; F Maesen
Journal:  Infection       Date:  1979       Impact factor: 3.553

9.  Pefloxacin in acute exacerbations of chronic bronchitis.

Authors:  F P Maesen; B I Davies; J P Teengs
Journal:  J Antimicrob Chemother       Date:  1985-09       Impact factor: 5.790

10.  Comparative activities of ciprofloxacin (Bay o 9867), norfloxacin, pipemidic acid, and nalidixic acid.

Authors:  H L Muytjens; J van der Ros-van de Repe; G van Veldhuizen
Journal:  Antimicrob Agents Chemother       Date:  1983-08       Impact factor: 5.191

View more
  12 in total

Review 1.  Enoxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  J M Henwood; J P Monk
Journal:  Drugs       Date:  1988-07       Impact factor: 9.546

2.  Pharmacokinetic quantification of the exchange of drugs between blood and cerebrospinal fluid in man.

Authors:  R Nau; G Zysk; A Thiel; H W Prange
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 3.  Pefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  J P Gonzalez; J M Henwood
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

4.  Steady-state pharmacokinetics and sputum penetration of lomefloxacin in patients with chronic obstructive pulmonary disease and acute respiratory tract infections.

Authors:  J M Kovarik; A I Hoepelman; J M Smit; P A Sips; M Rozenberg-Arska; J H Glerum; J Verhoef
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

5.  The influence of quinolone derivatives on theophylline clearance.

Authors:  W J Wijnands; T B Vree; C L van Herwaarden
Journal:  Br J Clin Pharmacol       Date:  1986-12       Impact factor: 4.335

Review 6.  Ofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  J P Monk; D M Campoli-Richards
Journal:  Drugs       Date:  1987-04       Impact factor: 9.546

7.  The influence of the 4-quinolones ciprofloxacin, pefloxacin and ofloxacin on the elimination of theophylline.

Authors:  W J Wijnands; T B Vree; A M Baars; C L van Herwaarden
Journal:  Pharm Weekbl Sci       Date:  1987-12-11

8.  Respiratory infections: clinical experiences with the new quinolones.

Authors:  B I Davies; F P Maesen
Journal:  Pharm Weekbl Sci       Date:  1987-12-11

Review 9.  Pefloxacin clinical pharmacokinetics.

Authors:  F Bressolle; F Gonçalves; A Gouby; M Galtier
Journal:  Clin Pharmacokinet       Date:  1994-12       Impact factor: 6.447

Review 10.  Pharmacokinetic disposition of quinolones in human body fluids and tissues.

Authors:  F Sörgel; U Jaehde; K Naber; U Stephan
Journal:  Clin Pharmacokinet       Date:  1989       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.